Cancer Gene Panels
XING Cancer Care offers a range of cancer gene panels for both newly diagnosed cancer patients and patients dealing with a recurrence of their disease. We perform cancer genetic testing to determine your patients likely response to certain drug therapies and clinical trials. Our aim is to provide you with a personalised report that may highlight clinically relevant genetic mutations to help you make informed choices on the best treatment options for your patients.
Please refer to the available gene panels below.
Homologous Recombination Deficiency (HRD)
The HRD panel is a multi-gene test that analyses the entire coding regions of 27 key genes involved in homologous recombination repair deficiency. This panel is aimed at breast, ovarian, prostate, and pancreatic cancers.
Solid Tumour Panel (STP)
The STP panel is a multi-gene test that analyses hotspot alterations considered to be driving mutations in solid tumours; includes hotspots in 47 genes involved in colorectal, melanoma, NSCLC, pancreatic, GIST, and glioma.
The XGP72 panel is a multi-gene test for cancer predisposition and targeted treatment. The test analyses coding regions of 72 of the most clinically relevant genes that are commonly associated with cancer or with an increased risk for cancer.